Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) hit a new 52-week low during mid-day trading on Monday . The company traded as low as C$1.15 and last traded at C$1.17, with a volume of 121921 shares traded. The stock had previously closed at C$1.18.
Analysts Set New Price Targets
Separately, Raymond James upgraded Oncolytics Biotech to a "moderate buy" rating in a report on Thursday, November 14th.
Read Our Latest Stock Analysis on Oncolytics Biotech
Oncolytics Biotech Stock Performance
The business has a 50 day simple moving average of C$1.51 and a 200-day simple moving average of C$1.41. The company has a current ratio of 4.99, a quick ratio of 8.86 and a debt-to-equity ratio of 6.09. The stock has a market capitalization of C$90.69 million, a price-to-earnings ratio of -3.11 and a beta of 1.35.
About Oncolytics Biotech
(
Get Free Report)
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Oncolytics Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.
While Oncolytics Biotech currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
